Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial

The Lancet Respiratory Medicine

Volumn 6, Issue 7, 2018, Pages 499-510

  Russell, Richard J ^a   Chachi, Latifa ^a   FitzGerald, J Mark ^b   Backer, Vibeke ^c   Olivenstein, Ronald ^d   Titlestad, Ingrid L ^e   Ulrik, Charlotte Suppli ^f   Harrison, Timothy ^g   Singh, Dave ^h   Chaudhuri, Rekha ^i,j   Leaker, Brian ^k   McGarvey, Lorcan ^l   Siddiqui, Salman ^a   Wang, Millie ^m   Braddock, Martin ^m   Nordenmark, Lars H ⁿ   Cohen, David ^m   Parikh, Himanshu ^m   Colice, Gene ^m   Brightling, Christopher E ^a   Laviolette, Michel ^o   Skjold, Tina ^o   Nielsen, Læge Carl ^o   Howarth, Peter ^o   more..

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

^f HVIDOVRE HOSPITAL   (Denmark)

^g UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^h UNIVERSITY OF MANCHESTER   (United Kingdom)

ⁱ GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^j UNIVERSITY OF GLASGOW   (United Kingdom)

^k RESPIRATORY CLINICAL TRIALS LTD   (United Kingdom)

^l QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^m ASTRAZENECA   (United Kingdom)

ⁿ ASTRAZENECA R AND D   (Sweden)

^o NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 4; FIBRONECTIN; FLUTICASONE; IMMUNOGLOBULIN E; PLACEBO; TRALOKINUMAB; TRANSFORMING GROWTH FACTOR BETA; MONOCLONAL ANTIBODY;

ADULT; ADVERSE EVENT; AGED; AIRWAY REMODELING; AIRWAY RESISTANCE; ALLERGIC AIRWAY INFLAMMATION; ARTICLE; ASTHMA; BREAST DISEASE; BRONCHUS BIOPSY; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG STABILITY; DRUG WITHDRAWAL; EOSINOPHIL COUNT; EOSINOPHILIC AIRWAY INFLAMMATION; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; FRACTIONAL EXHALED NITRIC OXIDE; GASTROINTESTINAL DISEASE; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPATHOLOGY; INFLAMMATORY CELL; INJECTION SITE REACTION; INTERACTIVE VOICE RESPONSE SYSTEM; LYMPHATIC SYSTEM DISEASE; MALE; MENTAL DISEASE; METABOLIC DISORDER; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; TREATMENT DURATION; TREATMENT RESPONSE; VASCULAR DISEASE; VIRAL UPPER RESPIRATORY TRACT INFECTION; ADOLESCENT; BRONCHUS; CANADA; CLINICAL TRIAL; DENMARK; DRUG EFFECT; EOSINOPHILIA; INFLAMMATION; MIDDLE AGED; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNITED KINGDOM; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ASTHMA; BRONCHI; CANADA; DENMARK; DOUBLE-BLIND METHOD; EOSINOPHILIA; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNITED KINGDOM; YOUNG ADULT;

EID: 85047208099     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(18)30201-7     Document Type: Article

References (33)

1. Global Initiative for Asthma. Global strategy for asthma management and prevention. http://ginasthma.org/2018-gina-report-global-strategy-for-asthma-management-and-prevention/, 2018. (Accessed 28 February 2018)
2. Chung, KF, Wenzel, SE, Brozek, JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 43 (2014), 343–373.
3. Papi, A, Brightling, C, Pedersen, SE, Reddel, HK, Asthma. Lancet 391 (2018), 783–800.
4. Pavord, ID, Beasley, R, Agusti, A, et al. After asthma: redefining airways diseases. Lancet 391 (2018), 350–400.
5. Diver, S, Russell, RJ, Brightling, C, New and emerging drug treatments for severe asthma. Clin Exp Allergy 48 (2018), 241–252.
6. Brightling, CE, Saha, S, Hollins, F, Interleukin-13: prospects for new treatments. Clin Exp Allergy 40 (2010), 42–49.
7. Piper, E, Brightling, C, Niven, R, et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J 41 (2013), 330–338.
8. Brightling, CE, Chanez, P, Leigh, R, et al. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med 3 (2015), 692–701.
9. Panettieri, RA Jr, Sjöbring, U, Péterffy, AM, et al. Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials. Lancet Respir Med, 2018 published online May 20. http://dx.doi.org/10.1016/S2213-2600(18)30184-X.
10. Castro, M, Zangrilli, J, Wechsler, ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 3 (2015), 355–366.
11. Ortega, HG, Liu, MC, Pavord, ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 371 (2014), 1198–1207.
12. FitzGerald, JM, Bleecker, ER, Nair, P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 388 (2016), 2128–2141.
13. Bleecker, ER, FitzGerald, JM, Chanez, P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 388 (2016), 2115–2127.
14. George, L, Brightling, CE, Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease. Ther Adv Chronic Dis 7 (2016), 34–51.
15. Laviolette, M, Gossage, DL, Gauvreau, G, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol, 132, 2013, 1086 96.e5.
16. Flood-Page, PT, Menzies-Gow, AN, Kay, AB, Robinson, DS, Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 167 (2003), 199–204.
17. Hartley, RA, Barker, BL, Newby, C, et al. Relationship between lung function and quantitative computed tomographic parameters of airway remodeling, air trapping, and emphysema in patients with asthma and chronic obstructive pulmonary disease: a single-center study. J Allergy Clin Immunol, 137, 2016, 1413 22.e12.
18. Galban, CJ, Han, MK, Boes, JL, et al. Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. Nat Med 18 (2012), 1711–1715.
19. Brightling, CE, Nordenmark, LH, Jain, M, et al. Effect of anti-IL-13 treatment on airway dimensions in severe asthma. Am J Respir Crit Care Med 194 (2016), 118–120.
20. Hanania, NA, Korenblat, P, Chapman, KR, et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med 4 (2016), 781–796.
21. Corren, J, Lemanske, RF, Hanania, NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 365 (2011), 1088–1098.
22. Green, RH, Brightling, CE, McKenna, S, et al. Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness. Eur Respir J 27 (2006), 1144–1151.
23. Fingleton, J, Braithwaite, I, Travers, J, et al. Serum periostin in obstructive airways disease. Eur Respir J 47 (2016), 1383–1391.
24. Sweeney, J, Brightling, CE, Menzies-Gow, A, et al. Clinical management and outcome of refractory asthma in the UK from the British Thoracic Society Difficult Asthma Registry. Thorax 67 (2012), 754–756.
25. Laporte, JC, Moore, PE, Baraldo, S, et al. Direct effects of interleukin-13 on signaling pathways for physiological responses in cultured human airway smooth muscle cells. Am J Respir Crit Care Med 164 (2001), 141–148.
26. Tliba, O, Deshpande, D, Chen, H, et al. IL-13 enhances agonist-evoked calcium signals and contractile responses in airway smooth muscle. Br J Pharmacol 140 (2003), 1159–1162.
27. Haldar, P, Brightling, CE, Hargadon, B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 360 (2009), 973–984.
28. Castro, M, Wenzel, SE, Bleecker, ER, et al. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med 2 (2014), 879–890.
29. Corren, J, Parnes, JR, Wang, L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med 377 (2017), 936–946.
30. Wenzel, S, Castro, M, Corren, J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet 388 (2016), 31–44.
31. Regeneron/Sanofi. Regeneron and Sanofi announce positive dupilumab topline results from phase 3 trial in uncontrolled persistent asthma. http://investor.regeneron.com/releasedetail.cfm?releaseid=1039754, 2017. (Accessed 28 February 2018)
32. Fichtner-Feigl, S, Strober, W, Kawakami, K, Puri, RK, Kitani, A, IL-13 signaling through the IL-13α2 receptor is involved in induction of TGF-β1 production and fibrosis. Nat Med 12 (2006), 99–106.
33. Gonem, S, Berair, R, Singapuri, A, et al. Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial. Lancet Respir Med 4 (2016), 699–707.